BioXcel Therapeutics, Inc. Aktie News
2,54 $
0,03 %
heute
Nasdaq,
13. Oktober, 19:46 Uhr
tracken
BioXcel Therapeutics, Inc. Aktie News
Neutral
GlobeNewsWire
●
etwa 7 Stunden alt
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO Vimal Mehta, Ph.D., and members of the BioXcel team will ring the Nasdaq Stock Market Closing Bell on Tuesday, October 14, 2025. This honor marks a pi...
Neutral
GlobeNewsWire
●
25 Tage alt
NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the...
Neutral
Seeking Alpha
●
etwa ein Monat alt
BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Discuses on SERENITY At-Home Pivotal Phase 3 Safety Trial Results Conference September 10, 2025 02:00 PM ET Company Participants Vimal Mehta - Founder, CEO, President, & Director Leslie Citrome - Clinical Professor of Psychiatry and Behavioral Sciences, New York Medical College Conference Call Participants Sumant Kulkarni - Canaccord Genuity Corp., Rese...
Neutral
GlobeNewsWire
●
etwa ein Monat alt
BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p
Neutral
GlobeNewsWire
●
etwa ein Monat alt
NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D.
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia
Positiv
Reuters
●
etwa 2 Monate alt
BioXcel Therapeutics said on Wednesday its experimental agitation drug met the main goal of a late-stage study testing it in patients with bipolar disorder or schizophrenia for at-home use.
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
